Muna Therapeutics

Executive Summary

Muna Therapeutics is a Copenhagen-based biotechnology company founded in 2020, dedicated to developing small molecule therapies that slow or halt the progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s unique strategy centers on enhancing the brain’s intrinsic resilience mechanisms, aiming to protect neurons and restore function rather than merely targeting single pathological hallmarks like amyloid plaques or tau tangles. Muna’s discovery platform leverages insights from human genetics, neurobiology, and phenotypic screening to identify novel targets and drug candidates that modulate key pathways involved in neuroprotection and synaptic health. While the company remains private and has not disclosed its financial details or specific pipeline assets, its focus on disease-modifying treatments for large unmet needs positions it within a highly active therapeutic area. Early preclinical data, if any, have not been publicly released, and the company is likely still in the lead optimization or IND-enabling stage. Muna operates with a lean model, typical of early-stage European biotechs, and may seek to partner or raise capital to advance its most promising candidates toward clinical development. The success of its approach hinges on translational validation and differentiation from competitors pursuing similar resilience-based strategies.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round60% success
• Q4 2026Lead Program Nomination and IND-Enabling Studies Initiation40% success
• Q2 2026Publication of Preclinical Proof-of-Concept Data in a Peer-Reviewed Journal50% success